Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 16/20 | 0.58 |
| ▸ | JAK3 | P52333 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.45 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.45 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.45 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.45 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.45 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.45 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.45 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20164954 | 0.88 | JAK2 (0.58) | JAK2JAK3GABRA1GABRG2GABRB3 | |
| SCHEMBL18132018 | 0.86 | JAK2 (0.56) | JAK2JAK3KDM4EALDH1A1MAPT | |
| SCHEMBL18132112 | 0.85 | JAK2 (0.71) | JAK2JAK3KDM4EALDH1A1MAPT | |
| SCHEMBL3612956 | 0.84 | NR4A2 (0.51) | JAK2KDM4EALDH1A1MAPTMAPK1 | |
| SCHEMBL18138200 | 0.80 | JAK2 (0.53) | JAK2JAK3KDM4EALDH1A1PARP1 | |
| SCHEMBL20164977 | 0.80 | NR4A2 (0.45) | JAK2 | |
| SCHEMBL1370456 | 0.79 | MAPT (0.46) | JAK2KDM4EALDH1A1MAPTPARP1 | |
| SCHEMBL13819048 | 0.77 | KDM4E (0.52) | JAK2JAK3KDM4EALDH1A1MAPT | |
| SCHEMBL3621428 | 0.77 | KDM4E (0.52) | JAK2JAK3KDM4EALDH1A1MAPT | |
| SCHEMBL3602841 | 0.74 | JAK2 (1.00) | JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3280418-B1 | AZACARBAZOLE BTK INHIBITORS | MERCK SHARP & DOHME (US) | 2020-05-06 | — | — | EP | disclosed |
| US-20180141962-A1 | AZACARBAZOLE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141962-A1 | AZACARBAZOLE BTK INHIBITORS | BTK, SYK, LYN | JAK2 6/4885JAK3 152/4885KDM4E 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.